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Abstract Cell migration over or through the extracellular
matrix (ECM) is an integral feature of both physiological and
pathological processes. Regulation of the changing cell^ECM
interactions involved can be effected by proteolysis and requires
strict spatial and temporal targeting of proteinase activity.
The versatile use of different proteinase systems, with a variety
of localisation mechanisms and cleavage targets, is being
revealed by a plethora of studies using in vitro models. This
mini review reflects the status of our knowledge of strategies for
the localisation of proteolytic activity effected during cell
migration. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Serine proteinases: old and new
Serine proteinases, and in particular those of the plasmino-
gen activator/plasmin system, have been implicated in the mi-
gration and invasion of cells since the early 1970s when onco-
genic transformation of cells was ¢rst shown to upregulate the
expression of plasminogen activators and by the histological
localisation of the plasminogen activators to actively invasive
foci of experimental tumours (as described in the landmark
review of DanÖ et al.) [1]. However the concept that the func-
tion of these proteinases might be dependent on membrane
targeting (Fig. 1) did not emerge until the identi¢cation of
uPAR, the speci¢c high a⁄nity receptor for the plasminogen
activator uPA, in the late 1980s. This molecule has since gen-
erated a lot of interest as it appears that by targeting uPA to
the plasma membrane, uPAR acts as a focal point for the
assembly of multimolecular complexes that dynamically regu-
late plasmin generation and activity and modulate cell adhe-
sion and signalling.
The binding of uPA, or its zymogen form pro-uPA, to
uPAR on the plasma membrane greatly accelerates plasmino-
gen activation [2]. This is not due to direct e¡ects of uPAR on
uPA catalytic activity as soluble uPAR does not enhance
plasminogen activation [3], and recently it has been shown
that uPAR-bound uPA mediates the assembly of catalytically
favoured complexes with cell-associated plasminogen [4].
These interactions facilitate the process of reciprocal zymogen
activation, i.e. the activation of plasminogen by uPA and the
activation of pro-uPA by plasmin, and increase the catalytic
e⁄ciencies of both reactions primarily due to e¡ects on their
Km. The e⁄ciency of this system is such that, at least in vitro,
it can circumvent the need for exogenous proteolytic activa-
tion and can be initiated by the low intrinsic catalytic activity
present in pro-uPA [5]. The activity of this system has an
absolute dependence on plasminogen binding, although this
appears to be a relatively non-selective phenomenon as a
range of molecules have been demonstrated to bind plasmin-
ogen at the cell surface with a⁄nities in the low WM range.
The common feature amongst these molecules, which include
K-enolase, annexin II and cytokeratin 8 [6^8], is that they have
C-terminal lysine residues. These residues are either present in
the native protein or exposed by limited proteolysis, and are
the preferred ligand for the kringle modules of plasminogen.
The large capacity of cells to bind plasminogen suggests that
this is part of the activation mechanism, but it is possible that
a small sub-set of the plasminogen binding molecules is func-
tionally favoured, e.g. by speci¢c co-localisation with uPAR.
This concept is supported by a number of lines of evidence,
including kinetic modelling which demonstrates that simple
stoichiometric complex formation can give catalytic e⁄cien-
cies equivalent to those observed for the system assembled on
the plasma membrane [5]. Although uPAR strictly targets
plasmin generation to the plasma membrane, this plasmin
dissociates from the cell surface within minutes giving the
possibility that it does not act locally. However an alternative
mechanism appears to be used to con¢ne the activity of plas-
min to the local environment, as dissociated plasmin is very
rapidly inactivated by the abundant plasma inhibitor K2-anti-
plasmin, whereas cell-associated plasmin is almost completely
protected from inhibition [2]. Therefore plasmin activity is
dynamically regulated at the cell surface, with K2-antiplasmin
suppressing the dissemination of plasmin activity and PAI-1
inhibiting its generation.
In spite of the abundance of observations both in vitro and
in vivo [9] implicating uPAR in the regulation of plasmin
generation, mice with ablation of the uPAR gene have no
overt physiological phenotype [10]. This re£ects both the re-
dundancy that has become evident in matrix-degrading pro-
teolytic systems and the very precisely controlled levels of
proteolytic activity required for cell migration in pathological
situations. An excellent example of this is the observation that
although plasmin generation is implicated in the pericellular
proteolysis necessary for angiogenesis in vivo which is conse-
quently reduced in Plg3=3 mice, it is paradoxically also de-
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creased in PAI-13=3 mice [11]. Therefore, both reduced and
increased proteolytic activities are non-permissive for cell mi-
gration in this in vivo model.
How then do migrating cells utilise the activity of this sys-
tem in the absence of a direct linkage of the glycophospholi-
pid (GPI)-anchored uPAR to the cytoskeleton? The polarisa-
tion of uPAR to the leading edge of migrating cells was ¢rst
observed in monocytes [12] and has since been demonstrated
in a variety of cell types. In stationary cells uPAR is found
both in focal adhesions and lipid rafts including caveolae. The
presence of uPAR in the latter has been reported to lead to an
increase in uPAR-mediated proteolysis in some [13], but not
all, cell types [14]. The presence of uPAR in focal adhesions
and its polarisation in migrating cells is thought to be depen-
dent on interactions with other proteins and a number of
potential mechanisms for this have emerged involving direct
binding of uPA/uPAR to the adhesion protein vitronectin and
interactions with integrins. uPAR can support the adhesion of
leukocytes to vitronectin in an integrin-independent manner
[15] and over-expression studies in ¢broblasts have recently
shown that uPAR binding to vitronectin leads to a reorgan-
isation of the actin cytoskeleton and increases cell motility
through activation of a Rac-dependent signalling pathway
[16]. A variety of experiments have indirectly implied interac-
tions between uPAR and integrins of di¡erent classes and co-
immunoprecipitation studies have demonstrated interactions
with the L2-integrin Mac-1 (CD11b/CD18) [17]. The di⁄culty
in demonstrating these interactions directly may be that they
are transitory, at least in motile cells, as it has been shown by
FRET techniques that uPAR interactions with L2-integrins
oscillate in migrating neutrophils [18]. Computer modelling
studies have suggested that a direct transport mechanism is
involved in the translocation of uPAR to lamellipodia during
polarisation of these cells (i.e. it is not a di¡usional process)
[19], and this process may also be mediated by integrins. Both
L1- and L3-integrins have been shown to bind soluble uPAR
and suggested to be a mechanism for in trans uPAR^integrin
interactions [20].
An important question that has yet to be fully addressed is
whether these various interactions regulate cell adhesion, as
has been proposed by a number of groups, or regulate pro-
teolysis by directing uPAR-dependent proteolytic activity to
Fig. 1. Strategies for the targeting of serine and metalloproteinases to the cell surface. A: Serine proteinases: the GPI-anchored protein uPAR
binds uPA with high a⁄nity and speci¢city, but various other proteins have been shown to associate, or collaborate closely, with either uPAR
or the uPA/uPAR complex. These include vitronectin, integrins (KVL3, L1L2, e.g. in focal adhesion complexes) and other transmembrane recep-
tors and adaptors including the K2-macroglobulin receptor (K2M-R), also known as LRP, gp130 (potentially leading to intracellular signal
transduction), tetraspanins, uPARAP (or endo180), and intracellularly, the mannose-6-phosphate receptor (Man6P-R). Cells with cholesterol-
rich lipid rafts and caveolae can concentrate the GPI-anchored uPAR alongside numerous signalling pathways [67] which can regulate cell mi-
gration. Plasminogen is also cell-associated, notably by binding to cell surface proteins with C-terminal lysine residues, and this is necessary for
its e⁄cient activation. The family of TTSPs directly target proteolytic activity to the cell surface and tentative roles in cell migration have been
proposed for some of these activities. Seprase, a transmembrane serine peptidase, has been localised to the invading front (‘invadopodia’) of tu-
mour cells along with K3L1-integrin, and a role in cell migration has been proposed. B: Metalloproteinases: the membrane-associated MT1-
MMP has a proteolytic function in its own right and mediates the activation of the soluble pro-MMP-2 through the formation of a complex
with TIMP-2 which then acts as a pro-MMP-2 ‘receptor’. Clustering of MT1-MMP at the cell surface, possibly in association with integrins
(KVL3, K2L1, K3L1) or CD44, may promote the e⁄ciency of this activation cascade. Forms of MMP-2 may also bind to KVL3-integrin and to
ECM components such as collagen and heparan sulphate proteoglycans. Other soluble MMPs bind to collagen, including the speci¢c collage-
nases MMP-1, -8 and -13, as well as non-collagenolytic MMPs, MMP-3 and -9. Recently MMP-1 was found to bind to the I domain of the
K2 chain of the integrin K2L1. An association between CD44 and MMP-9 at the cell surface has also been described.
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the relevant area of the cell surface and/or by dynamically
a¡ecting the activity of the system. There is some support
for the latter, as vitronectin-dependent relocalisation of
uPAR to focal adhesions has been reported to reduce cell
surface uPA activity [21] and it has been observed that certain
members of the tetraspan family of integrin-interacting pro-
teins can in£uence the uPA/uPAR interaction (Ellis, Bass and
Berditchevski, unpublished observations). The e¡ective func-
tion of uPAR-mediated proteolysis in cell migration also ap-
pears to be regulated by the low density lipoprotein (LDL)
receptor-related protein LRP [22], which acts to clear uPAR-
bound uPA^PAI-1 complexes from the cell surface leading to
a recycling of unoccupied uPAR [23], presumably leading to
further cycles of activation and inhibition. The C-type lectin
endo180 (uPAR-associated protein (uPARAP)) has recently
been shown to speci¢cally associate with the uPA/uPAR com-
plex [24].
The binding of a secreted proteinase to a plasma membrane
receptor or binding site as a mechanism targeting proteolytic
activity allows the possibility of paracrine interactions. In the
uPAR system such interactions have been shown to be of
importance in a number of human cancers where cancer cells
and stromal cells collaborate in proteolysis [25]. However di-
rect targeting of proteolytic activity to the plasma membrane
also occurs in the serine proteinase sub-family known as the
type II transmembrane serine proteinases (TTSPs). These pro-
teinases have recently been reviewed [26], so we will focus here
on those that may be involved in cell migration and invasion
as they were either initially identi¢ed as tumour-associated
genes or have been found to be upregulated in tumours. These
include TMPRSS-2, TMPRSS-4 and matriptase (also known
as MT-SP1, TADG-15 or epithin). These proteinases are pre-
dicted to have a trypsin-like speci¢city, although biochemical
analysis has only been carried out with matriptase, which has
been shown to both directly degrade extracellular matrix
(ECM) [27] and to activate pro-uPA [28,29]. The latter obser-
vation raises the possibility that matriptase could be an ini-
tiator of a proteolytic cascade leading to plasmin generation.
However it is not yet known whether this activation can take
place in the cellular context with transmembrane matriptase
and uPAR-bound pro-uPA, as these studies were performed
in solution with the isolated proteinase domain of matriptase.
Interestingly the modules present N-terminally of the protease
domain in these proteins are rarely found in other mosaic
serine proteinases and include LDL receptor class A, scav-
enger receptor cysteine-rich and CUB domains. In many other
proteins these domains are associated with protein^protein
interactions and ligand binding, giving the possibility that
they are involved in substrate recognition by these proteinases
and/or used to target them to speci¢c regions of the plasma
membrane. The elucidation of the biological roles of these
proteinases is likely to be an area of intense research over
the coming years, with identi¢cation of their substrates and
the functions of their ancillary domains being key issues.
Another transmembrane proteinase potentially involved in
migration and invasion is seprase, which although a serine
proteinase is completely distinct from the trypsin-like protein-
ases discussed here, it has an K/L-hydrolase fold and is related
to dipeptidyl peptidase-IV (CD26). Seprase has gelatinolytic
activity and has been shown to localise to invadapodia where
it associates with the K3L1-integrin in a collagen-dependent
manner [30], Fig. 1.
2. Metalloproteinases move in on the act
The matrix metalloproteinases (MMPs) have been impli-
cated in cell migration and invasion in both model systems
and in vivo by the observation that inhibitors of metallopro-
teinases frequently, although not always, abrogate such
events. Since many MMPs are secreted as soluble proteins
the question arises as to how their function might be spatially
regulated. Synthesis and secretion of soluble MMPs by cells at
speci¢c locations may occur, e.g. the front of migrating epi-
thelial sheets, as seen for MMP-1 and MMP-10 in keratino-
cytes [31], MMP-9 in bronchial epithelial cells [32] and MMP-
2 in mammary epithelial cells [33], and the activation of se-
creted proforms of the MMPs by the plasmin cascade may to
some extent con¢ne function to a relatively speci¢ed pericel-
lular environment [34]. MMP-2 and -9 have domains related
to the type II repeats in ¢bronectin which bind both collagens
and gelatin, allowing e⁄cient ECM sequestration. Many of
the collagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3)
have C-terminal hemopexin-like domains that bind to colla-
gen. MMP-9 has been found in association with the heparan
sulphate-containing CD44v3; 8ÿ10 splice variant displayed on
the membrane of invadopodial structures of a breast cancer
cell line, Fig. 1. This form of CD44 is known to be preferen-
tially expressed on the surface of metastatic tumour cells and
to promote cell migration. Hyaluronan-mediated clustering of
CD44 appeared to be a feature of the co-localisation of CD44
and MMP-9 [35,36]. A precise role for the heparan sulphate
proteoglycan has not been shown, but the concept of seques-
tration of some proteinases on the charged glycosaminoglycan
chains seems reasonable. It has also been shown that pro-
MMP-9 binds relatively tightly to the K2 chain of type IV
collagen [37] and can form a heterodimer with the chondroitin
sulphate proteoglycan core protein [38]. This is interesting in
the light of a study of pulmonary epithelial cell migration in a
monolayer ‘wound’ model, where MMP-9 and type IV colla-
gen secretion may be seen in cells with an active migratory
phenotype. Their localisation coincides with those of vinculin
and actin, i.e. at substratum contacts [32]. In this study the
role of integrins was not speci¢cally addressed, but in view of
the known association of integrins with the uPA/uPAR system
(see above), the question of interactions between integrins and
their associated signalling assemblies and MMPs is an impor-
tant one. In keratinocyte migration it is thought that there is a
close association between MMP-1 and the K2-integrin subunit.
MMP-1 was shown to bind to the A domain of the K2-integ-
rin in a cation-dependent manner. MMP-1 and type I collagen
appear to bind at di¡erent sites, however, as a mutated I
domain which no longer binds type I collagen can still bind
to MMP-1. Hence MMP-1 may be tightly focused to the
leading edge of the migrating keratinocyte [39]. An interaction
between MMP-2 and the integrin KVL3 was originally de-
scribed in endothelial cells and thought to be important for
the promotion of angiogenesis [40]. This interaction is turning
out to be more complex than at ¢rst study and is discussed
below in the light of new data.
The discovery of the membrane-type (MT)-MMPs that are
genuinely associated with the plasma membrane, including the
membrane spanning forms MT1-, 2-, 3- and 5-MMP (MMPs
14, 15, 16 and 24) and the GPI-anchored forms MT4- and
MT6-MMP (MMPs 17 and 25), has elicited a hugely exciting
new area of research activity in relation to the mechanism for
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focused proteolysis of the ECM, including in relation to cell
movement. All these enzymes are e⁄cient ECM-degrading
proteinases in their own right. Studies on tubulogenesis of
endothelial and MDCK cells have implicated the activity of
MT1-MMP, but the mechanism of its action is not known
[41^43]. Hotary et al. [44] have shown that MT1-MMP trans-
fection of MDCK cells promotes tubulogenesis in collagen
gels, but MT2-MMP and MT3-MMP di¡ered. They proposed
that distinct MT-MMPs promote invasive or morphogenic
responses according to the cell type and the matrix interac-
tions [45,46]. The involvement of MT1-MMP in osteoclast
migration and its association with lamellipodia and invadopo-
dia of these cells has been described. Interestingly, in non-
migrating osteoclasts MT1-MMP was evenly distributed in
dot-like structures at the cell membrane which co-localised
with actin [47]. MT1-MMP was found in the lamellipodia of
migratory mammary epithelial cells in an in vitro outgrowth
assay, as well as at their basal surface in contact with the
substrate [48]. Recently it was shown that MT1-MMP can
co-localise with and act as a CD44 processing activity, pro-
moting tumour cell migration [49], Fig. 1. MT1-MMP appears
to require its transmembrane domain and cytoplasmic tail to
localise to the invadopodia of tumour cells [50]. It has been
pointed out that the MT1-MMP cytoplasmic tail contains
potential T/S/Y phosphorylation sites that could be involved
in the recruitment of intracellular proteins that drive the spe-
ci¢c localisation of MT1-MMP [51]. The cytoplasmic tail of
MT1-MMP has been shown to bind the Golgi protein p59
(GRASP55) as does transforming growth factor K [52], but
the role of this association appears to be in intracellular traf-
¢cking of MT1-MMP. MT2-MMP appears to tra⁄c in a very
di¡erent fashion than MT1-MMP, and is largely con¢ned to
the Golgi when over-expressed in CHO cells [53]. MT3- and
MT5-MMP have not been studied in detail but have many
potential tra⁄cking motifs in common with MT1-MMP. The
potential localisation and role of the GPI-anchored MT4- and
MT6-MMPs have not yet been fully investigated. By analogy
with GPI-anchored uPAR, it may be that focusing of their
activity into large molecular complexes occurs by the binding
of adaptor proteins and integrins.
The membrane spanning MT-MMPs, notably MT1-MMP,
have achieved most notoriety as the activators of MMP-2.
The mechanism of activation has been well studied for
MT1-MMP and involves the sequestration of MMP-2 on a
‘receptor’ involving MT1-MMP/TIMP-2 complexes at the cell
surface, followed by propeptide cleavage, Fig. 1. The removal
of the propeptide occurs by sequential proteolysis by MT1-
MMP followed by MMP-2. This process appears to be regu-
lated by the clustering of MT1-MMP/TIMP-2, and hence
MMP-2, to allow an e⁄cient catalytic cascade to be invoked.
Interestingly, when MMP-2 activation is at its most e⁄cient,
MT1-MMP is destroyed, apparently by self-cleavage in the
C-terminal region of the catalytic domain, yielding 40^43 kDa
forms still bound into the membrane [54^56]. Further evalua-
tion of this process has invoked the involvement of KVL3 in
certain cell types. The integrin is thought to promote more
e⁄cient activation of MMP-2 by MT1-MMP by transient
binding of the cleaved propeptide intermediate and active
MMP-2. Co-expression of MT1-MMP and KVL3 in MCF7
carcinoma cells speci¢cally enhances in trans autocatalytic
maturation of MMP-2. Clustering of MT1-MMP and KVL3
at discrete regions of the cell surface could be observed by
immunolocalisation and was proposed to be an important
mechanism for the clustering of MMP-2 at the invasive front
of cells utilising KVL3 as part of the migratory process. The
work of Puyraimond [57] has shown co-localisation of MMP-
2/MT1-MMP/TIMP-2/KVL3 in caveolae. Since MMP-2 is
known to interact with KVL3 through its hemopexin-like do-
main, the mechanism for speci¢c binding of the MMP-2 at
certain stages of propeptide processing requires further study.
However, the general concept of MT1-MMP/integrin associ-
ations is an attractive one. In other cell types the aggregation
of L1-integrins has been suggested as a key event in MMP-2
activation by MT1-MMP [51,56,58] and co-localisation of
MT1-MMP and L1 integrins has been observed [59]. MT1-
MMP and MMP-2 have collagenolytic properties and their
concentration at the cell surface would represent a powerful
and highly localised means of regulating cell^collagen inter-
actions [60]. The phenotype of the mouse with an ablation of
the gene for MT1-MMP includes features which suggest a
major role in collagen turnover in joint tissues [61] and in
angiogenesis [62].
Other membrane-associated metalloproteinases, notably the
ADAMs (a disintegrin and a metalloproteinase) family, and
the astacins have been described in recent years [63^65]. They
have been ascribed roles in the proteolysis of a number of cell
surface proteins and ECM components but no direct role in
cell migration has been established. They appear to be parti-
ally regulated by tra⁄cking in the cell but little has been
documented as yet. Soluble versions of the ADAMs, the
ADAM-TS, have thrombospondin-1-like repeats which bind
to heparan sulphate proteoglycans and could also potentially
be focused at speci¢c cell surface locations [66].
3. Conclusions
The number of both soluble and membrane-bound protein-
ases that can be focused by the cell to act at speci¢c sites
continues to be documented, and an astonishing array of cel-
lular tactics to e¡ect the spatial localisation of proteolytic
activity is emerging. It is likely that the association of protein-
ases with other cellular or pericellular components will modify
their function, not only by the concentration of their activity
but by the subtle modi¢cation of substrate binding or specif-
icity and also of the interaction with inhibitors and other
e¡ectors.
Acknowledgements: Apologies to all those whose work has not been
cited due to the lack of space. Thanks to Dylan Edwards for discus-
sions and to all our colleagues for their contributions to our research.
Research in the authors’ laboratories is supported by the British Heart
Foundation (V.E.) and by the Medical Research Council and the
Wellcome Trust (G.M.).
References
[1] DanÖ, K., Andreasen, P.A., GrÖndahl-Hansen, J., Kristensen, P.,
Nielsen, L.S. and Skriver, L. (1985) Adv. Cancer Res. 44,
139^266.
[2] Ellis, V., Behrendt, N. and DanÖ, K. (1991) J. Biol. Chem. 266,
12752^12758.
[3] Ellis, V. (1996) J. Biol. Chem. 271, 14779^14784.
[4] Ellis, V., Whawell, S.A., Werner, F. and Deadman, J.J. (1999)
Biochemistry 38, 651^659.
[5] Ellis, V. and DanÖ, K. (1993) J. Biol. Chem. 268, 4806^4813.
[6] Redlitz, A., Fowler, B.J., Plow, E.F. and Miles, L.A. (1995) Eur.
J. Biochem. 227, 407^415.
FEBS 25247 26-9-01
V. Ellis, G. Murphy/FEBS Letters 506 (2001) 1^54
[7] Hajjar, K.A., Jacovina, A.T. and Chacko, J. (1994) J. Biol.
Chem. 269, 21191^21197.
[8] Hembrough, T.A., Li, L. and Gonias, S.L. (1996) J. Biol. Chem.
271, 25684^25691.
[9] Zhou, H.M., Nichols, A., Meda, P. and Vassalli, J.D. (2000)
EMBO J. 19, 4817^4826.
[10] Bugge, T.H., Suh, T.T., Flick, M.J., Daugherty, C.C., RÖmer, J.,
Solberg, H., Ellis, V., DanÖ, K. and Degen, J.L. (1995) J. Biol.
Chem. 270, 16886^16894.
[11] Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V.,
Praus, M., Lund, L.R., Frandsen, T.L., Bru«nner, N., DanÖ, K.,
Fusenig, N.E., Weidle, U., Carmeliet, G., Loskuto¡, D., Collen,
D., Carmeliet, P., Foidart, J.M. and Noe«l, A. (2001) J. Cell Biol.
152, 777^784.
[12] Estreicher, A., Muhlhauser, J., Carpentier, J.L., Orci, L. and
Vassalli, J.D. (1990) J. Cell Biol. 111, 783^792.
[13] Stahl, A. and Mueller, B.M. (1995) J. Cell Biol. 129, 335^344.
[14] Ellis, V. and Whawell, S.A. (1997) Blood 90, 2312^2322.
[15] Wei, Y., Waltz, D.A., Rao, N., Drummond, R.J., Rosenberg, S.
and Chapman, H.A. (1994) J. Biol. Chem. 269, 32380^32388.
[16] KjÖller, L. and Hall, A. (1999) Exp. Cell Res. 253, 166^179.
[17] Wei, Y., Lukashev, M., Simon, D.I., Bodary, S.C., Rosenberg,
S., Doyle, M.V. and Chapman, H.A. (1996) Science 273, 1551^
1555.
[18] Kindzelskii, A.L., Eszes, M.M., Todd III, R.F. and Petty, H.R.
(1997) Biophys. J. 73, 1777^1784.
[19] Weinand, R.G., Rosenspire, A.J. and Petty, H.R. (1999) J. The-
or. Biol. 197, 217^225.
[20] Tarui, T., Mazar, A.P., Cines, D.B. and Takada, Y. (2001)
J. Biol. Chem. 276, 3983^3990.
[21] Wilcox, S.A., Reho, T., Higgins, P.J., Tominna-Sebald, E. and
McKeown-Longo, P.J. (1996) Biochem. Cell Biol. 74, 899^910.
[22] Czekay, R.P., Kuemmel, T.A., Orlando, R.A. and Farquhar,
M.G. (2001) Mol. Biol. Cell 12, 1467^1479.
[23] Nykj×r, A., Conese, M., Christensen, E.I., Olson, D., Cremona,
O., Gliemann, J. and Blasi, F. (1997) EMBO J. 16, 2610^2620.
[24] Behrendt, N., Jensen, O.N., Engelholm, L.H., Mortz, E., Mann,
M. and DanÖ, K. (2000) J. Biol. Chem. 275, 1993^2002.
[25] DanÖ, K., RÖmer, J., Nielsen, B.S., Bjorn, S., Pyke, C., Rygaard,
J. and Lund, L.R. (1999) APMIS 107, 120^127.
[26] Hooper, J.D., Clements, J.A., Quigley, J.P. and Antalis, T.M.
(2001) J. Biol. Chem. 276, 857^860.
[27] Lin, C.Y., Anders, J., Johnson, M., Sang, Q.A. and Dickson,
R.B. (1999) J. Biol. Chem. 274, 18231^18236.
[28] Takeuchi, T., Harris, J.L., Huang, W., Yan, K.W., Coughlin,
S.R. and Craik, C.S. (2000) J. Biol. Chem. 275, 26333^26342.
[29] Lee, S.L., Dickson, R.B. and Lin, C.Y. (2000) J. Biol. Chem. 275,
36720^36725.
[30] Mueller, S.C., Ghersi, G., Akiyama, S.K., Sang, Q.X., Howard,
L., Pineiro-Sanchez, M., Nakahara, H., Yeh, Y. and Chen, W.T.
(1999) J. Biol. Chem. 274, 24947^24952.
[31] Parks, W.C. (1999) Wound Repair Regen. 7, 423^432.
[32] Legrand, C., Gilles, C., Zahm, J.M., Polette, M., Buisson, A.C.,
Kaplan, H., Birembaut, P. and Tournier, J.M. (1999) J. Cell Biol.
146, 517^529.
[33] Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson,
W.G. and Quaranta, V. (1997) Science 277, 225^228.
[34] Legrand, C., Polette, M., Tournier, J.M., de Bentzmann, S.,
Huet, E., Monteau, M. and Birembaut, P. (2001) Exp. Cell
Res. 264, 326^336.
[35] Bourguignon, L.Y., Gunja-Smith, Z., Iida, N., Zhu, H.B.,
Young, L.J., Muller, W.J. and Cardi¡, R.D. (1998) J. Cell. Phys-
iol. 176, 206^215.
[36] Yu, Q. and Stamenkovic, I. (1999) Genes Dev. 13, 35^48.
[37] Olson, M.W., Toth, M., Gervasi, D.C., Sado, Y., Ninomiya, Y.
and Fridman, R. (1998) J. Biol. Chem. 273, 10672^10681.
[38] Winberg, J.O., Kolset, S.O., Berg, E. and Uhlin-Hansen, L.
(2000) J. Mol. Biol. 304, 669^680.
[39] Dumin, J.A., Dickeson, S.K., Stricker, T.P., Bhattacharyya-Pak-
rasi, M., Roby, J.D., Santoro, S.A. and Parks, W.C. (2001)
J. Biol. Chem., in press.
[40] Brooks, P.C., Stro«mblad, S., Sanders, L.C., Von Schalscha, T.L.,
Aimes, R.T., Stetler-Stevenson, W.G., Quigley, J.P. and Cheresh,
D.A. (1996) Cell 85, 683^693.
[41] Kadono, Y., Shibahara, K., Namiki, M., Watanabe, Y., Seiki,
M. and Sato, H. (1998) Biochem. Biophys. Res. Commun. 251,
681^687.
[42] Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R. and Weiss, S.J.
(1998) Cell 95, 365^377.
[43] La£eur, M.A., Hollenberg, M.D., Atkinson, S.J., Knauper, V.,
Murphy, G. and Edwards, D.R. (2001) Biochem. J. 357, 107^
115.
[44] Hotary, K., Allen, E., Punturieri, A., Yana, I. and Weiss, S.J.
(2000) J. Cell Biol. 149, 1309^1323.
[45] Belie«n, A.T.J., Paganetti, P.A. and Schwab, M.E. (1999) J. Cell
Biol. 144, 373^384.
[46] Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K. and
Quaranta, V. (2000) J. Cell Biol. 148, 615^624.
[47] Sato, T., Ovejero, M.D., Hou, P., Heegaard, A.M., Kumegawa,
M., Foged, N.T. and Delaisse¤, J.M. (1997) J. Cell Sci. 110, 589^
596.
[48] Gilles, C., Polette, M., Coraux, C., Tournier, J.-M., Meneguzzi,
G., Munaut, C., Volders, L., Rouselle, P., Birembaut, P. and
Foidart, J.-M. (2001) J. Cell Sci., in press.
[49] Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H.
and Seiki, M. (2001) J. Cell Biol. 153, 893^904.
[50] Nakahara, H., Howard, L., Thompson, E.W., Sato, H., Seiki,
M., Yeh, Y.Y. and Chen, W.T. (1997) Proc. Natl. Acad. Sci.
USA 94, 7959^7964.
[51] Ellerbroek, S.M. and Stack, M.S. (1999) BioEssays 21, 940^
949.
[52] Kuo, A., Zhong, C., Lane, W.S. and Derynck, R. (2000) EMBO
J. 19, 6427^6439.
[53] Miyamori, H., Takino, T., Seiki, M. and Sato, H. (2000) Bio-
chem. Biophys. Res. Commun. 267, 796^800.
[54] Lehti, K., Lohi, J., Valtanen, H. and Keski-Oja, J. (1998) Bio-
chem. J. 334, 345^353.
[55] Hernandez-Barrantes, S., Toth, M., Bernardo, M.M., Yurkova,
M., Gervasi, D.C., Raz, Y., Sang, Q.A. and Fridman, R. (2000)
J. Biol. Chem. 275, 12080^12089.
[56] Stanton, H., Gavrilovic, J., Atkinson, S.J., d’Ortho, M.P., Ya-
mada, K.M., Zardi, L. and Murphy, G. (1998) J. Cell Sci. 111,
2789^2798.
[57] Puyraimond, A., Fridman, R., Lemesle, M., Arbeille, B. and
Menashi, S. (2001) Exp. Cell Res. 262, 28^36.
[58] Deryugina, E.I., Bourdon, M.A., Reisfeld, R.A. and Strongin, A.
(1998) Cancer Res. 58, 3743^3750.
[59] Ellerbroek, S.M., Wu, Y.I., Overall, C.M. and Stack, M.S. (2001)
J. Biol. Chem. 276, 24833^24842.
[60] Atkinson, S.J., Patterson, M.L., Butler, M.J. and Murphy, G.
(2001) FEBS Lett. 491, 222^226.
[61] Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer,
M., Kuznetsov, S.A., Mankani, M., Robey, P.G., Poole, A.R.,
Pidoux, I., Ward, J.M. and Birkedal-Hansen, H. (1999) Cell 99,
81^92.
[62] Zhou, Z.J., Apte, S.S., Soininen, R., Cao, R.H., Baaklini, G.Y.,
Rauser, R.W., Wang, J.M., Cao, Y.H. and Tryggvason, K.
(2000) Proc. Natl. Acad. Sci. USA 97, 4052^4057.
[63] Schlondor¡, J. and Blobel, C.P. (1999) J. Cell Sci. 112, 3603^
3617.
[64] Blobel, C.P. (2000) Curr. Opin. Cell Biol. 12, 606^612.
[65] Bond, J.S. and Beynon, R.J. (1995) Protein Sci. 4, 1247^1261.
[66] Hurskainen, T.L., Hirohata, S., Seldin, M.F. and Apte, S.S.
(1999) J. Biol. Chem. 274, 25555^25563.
[67] Ossowski, L. and Aguirre-Ghiso, J.A. (2000) Curr. Opin. Cell
Biol. 12, 613^620.
FEBS 25247 26-9-01
V. Ellis, G. Murphy/FEBS Letters 506 (2001) 1^5 5
